Program
huperzine A
Also written as “Huperzine A injection”, “Huperzine A Oral Solution” and “Huperzine A for Injection”.
Its studies are mostly in Brain Injuries · Sensation Disorders · Schizophrenia · Alzheimer Disease, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wanbangde Pharmaceutical Group | 32 open or running | phase 4since Apr 30, 2024 | Apr 27, 2024 | Dec 31, 2026phase 1 · NCT07784335 |
| Biomedisyn | 10 open or running | phase 2since Aug 10, 2009 | Aug 10, 2009 | none ahead |
| Jiangsu Famous Medical Technology | 10 open or running | phase 4since Jul 22, 2020 | Jul 22, 2020 | none ahead |
| Luye Pharma Group | 10 open or running | phase 3since Jan 24, 2011 | Jan 24, 2011 | none ahead |
| Supernus Pharmaceuticals | 10 open or running | phase 1since May 15, 2017 | May 15, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 10, 2009First study: phase 2 study in SchizophreniaNew to BiomedisynBiomedisyn · NCT00963846 · 56 enrolled · United States
- Jan 24, 2011Luye Pharma Group’s first study: phase 3 study in Alzheimer DiseaseNew to Luye Pharma GroupLuye Pharma Group · NCT01282619 · 390 enrolled · China
- May 15, 2017Supernus Pharmaceuticals’ first study: phase 1 study in Epilepsy, Complex PartialNew to Supernus PharmaceuticalsSupernus Pharmaceuticals · NCT03156439 · 8 enrolled · Australia
- Jul 22, 2020Jiangsu Famous Medical Technology’s first study: phase 4 study in Sensation DisordersNew to Jiangsu Famous Medical TechnologyJiangsu Famous Medical Technology · NCT04509323 · 20 enrolled · China
- Apr 27, 2024Wanbangde Pharmaceutical Group’s first study: phase 1 study in Healthy SubjectsNew to Wanbangde Pharmaceutical GroupWanbangde Pharmaceutical Group · NCT06570655 · 12 enrolled · China
- Apr 30, 2024Phase 4 study in Cognitive Impairment After Brain InjuryWanbangde Pharmaceutical Group · NCT06704334 · 50 planned · China
- Aug 13, 2026Phase 1 study in HealhtyWanbangde Pharmaceutical Group · NCT07784335 · 40 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in HealhtyWanbangde Pharmaceutical Group · NCT07784335
- Dec 31, 2026Primary completion: phase 4 study in Cognitive Impairment After Brain InjuryWanbangde Pharmaceutical Group · NCT06704334
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Donepezilrule | Eisai | phase 4 | 83 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
| Z 338rule | Zeria Pharmaceutical | phase 3 | 12 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07784335Healhty · China | 1 | Not yet recruiting | Wanbangde Pharmaceutical Group | Dec 31, 2026 | 40 |
| NCT06704334Cognitive Impairment After Brain Injury · China | 4 | Recruiting | Wanbangde Pharmaceutical Group | Dec 31, 2026 | 50 |
| NCT06570655Healthy Subjects · China | 1 | Completed | Wanbangde Pharmaceutical Group | Jun 20, 2024 | 12 |
| NCT04509323Sensation Disorders · China | 4 | UNKNOWN | Jiangsu Famous Medical Technology | Feb 28, 2021 | 20 |
| NCT03156439Epilepsy, Complex Partial · Australia | 1 | Completed | Supernus Pharmaceuticals | Sep 30, 2017 | 8 |
| NCT01282619Alzheimer Disease · China | 3 | UNKNOWN | Luye Pharma Group | Jun 2012 | 390 |
| NCT00963846Schizophrenia · United States | 2 | Completed | Biomedisyn | Dec 2012 | 56 |
How it is read
Names in the registry
- “Huperzine A injection”, 3 entries
- “Huperzine A Oral Solution”, 1 entry
- “Huperzine A for Injection”, 1 entry
- “BIS-001 ER”, 1 entry
- “huperzine 0.2 mg BID”, 1 entry
Conditions, from the studies’ own filings
- Brain Injuries, 1 study
- Sensation Disorders, 1 study
- Schizophrenia, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.